Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.

Rogers JE, Ajani JA.

J Clin Oncol. 2019 Oct 20;37(30):2805-2806. doi: 10.1200/JCO.19.01247. Epub 2019 Aug 29. No abstract available.

PMID:
31465257
2.

Pharmacotherapeutic considerations for elderly patients with colorectal cancer.

Rogers JE, Eng C.

Expert Opin Pharmacother. 2019 Dec;20(17):2139-2160. doi: 10.1080/14656566.2019.1657826. Epub 2019 Aug 28.

PMID:
31456458
3.

Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.

Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA.

Ann Surg. 2019 Jun 7. doi: 10.1097/SLA.0000000000003383. [Epub ahead of print]

PMID:
31188215
4.

Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.

Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA.

Oncology. 2019;96(5):252-258. doi: 10.1159/000496978. Epub 2019 Mar 20.

PMID:
30893708
5.

Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.

Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA.

Ann Surg. 2019 Jan 31. doi: 10.1097/SLA.0000000000003228. [Epub ahead of print]

PMID:
30720506
6.

Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required.

Eng C, Rogers JE.

Expert Opin Pharmacother. 2019 Apr;20(5):523-534. doi: 10.1080/14656566.2018.1561866. Epub 2019 Jan 8. Review.

PMID:
30590946
7.

Patient safety after implementation of a coproduced family centered communication programme: multicenter before and after intervention study.

Khan A, Spector ND, Baird JD, Ashland M, Starmer AJ, Rosenbluth G, Garcia BM, Litterer KP, Rogers JE, Dalal AK, Lipsitz S, Yoon CS, Zigmont KR, Guiot A, O'Toole JK, Patel A, Bismilla Z, Coffey M, Langrish K, Blankenburg RL, Destino LA, Everhart JL, Good BP, Kocolas I, Srivastava R, Calaman S, Cray S, Kuzma N, Lewis K, Thompson ED, Hepps JH, Lopreiato JO, Yu CE, Haskell H, Kruvand E, Micalizzi DA, Alvarado-Little W, Dreyer BP, Yin HS, Subramony A, Patel SJ, Sectish TC, West DC, Landrigan CP.

BMJ. 2018 Dec 5;363:k4764. doi: 10.1136/bmj.k4764.

8.
9.

Potentially curable gastric adenocarcinoma treated without surgery.

Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A Jr, Devine CE, Das P, Badgwell BD, Ajani JA.

Eur J Cancer. 2018 Jul;98:23-29. doi: 10.1016/j.ejca.2018.04.012. Epub 2018 May 30.

PMID:
29859338
10.

Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA.

Oncology. 2018;94(6):345-353. doi: 10.1159/000486720. Epub 2018 Apr 27.

11.

Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial.

Shimodaira Y, Slack RS, Harada K, Chen HC, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Blum MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Mares J, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Br J Cancer. 2018 Feb 6;118(3):331-337. doi: 10.1038/bjc.2017.423. Epub 2017 Dec 12.

12.

Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial.

Harada K, Wang X, Shimodaira Y, Sagebiel T, Bhutani MS, Lee JH, Weston B, Elimova E, Lin Q, Amlashi FG, Mizrak Kaya D, Lopez A, Blum Murphy MA, Roth JA, Swisher SG, Skinner HD, Hofstetter WL, Rogers JE, Thomas I, Maru DM, Komaki R, Walsh G, Ajani JA.

Target Oncol. 2018 Feb;13(1):99-106. doi: 10.1007/s11523-017-0540-3.

13.

Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma.

Shimodaira Y, Slack RS, Harada K, Bhutani MS, Elimova E, Staerkel GA, Sneige N, Erasmus J, Shiozaki H, Charalampakis N, Planjery V, Kaya DM, Amlashi FG, Blum MA, Skinner HD, Minsky BD, Maru DM, Hofstetter WL, Swisher SG, Mares JE, Rogers JE, Lin QD, Ross WA, Weston B, Lee JH, Ajani JA.

Oncotarget. 2017 May 23;8(45):79356-79365. doi: 10.18632/oncotarget.18119. eCollection 2017 Oct 3.

14.

Pharmacotherapy of Anal Cancer.

Rogers JE, Eng C.

Drugs. 2017 Sep;77(14):1519-1530. doi: 10.1007/s40265-017-0792-3. Review.

PMID:
28770514
15.

Parent-Provider Miscommunications in Hospitalized Children.

Khan A, Furtak SL, Melvin P, Rogers JE, Schuster MA, Landrigan CP.

Hosp Pediatr. 2017 Sep;7(9):505-515. doi: 10.1542/hpeds.2016-0190. Epub 2017 Aug 2.

16.

Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients.

Mizrak Kaya D, Dong X, Nogueras-González GM, Xu Y, Estrella JS, Harada K, Lopez A, Amlashi FG, Hofstetter WL, Maru DM, Nguyen QN, Lee JH, Weston B, Bhutani MS, Erasmus JJ, Thomas I, Rogers JE, Song S, Ajani JA.

Med Oncol. 2017 Aug;34(8):135. doi: 10.1007/s12032-017-0994-2. Epub 2017 Jul 6.

PMID:
28685276
17.

101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy.

Mizrak Kaya D, Wang X, Harada K, Blum Murphy MA, Das P, Minsky BD, Estrella JS, Lin Q, Amlashi FG, Lee JH, Weston B, Bhutani MS, Matamoros A Jr, Sagebiel T, Wu CC, Rogers JE, Thomas I, Maru DM, Skinner HD, Badgwell BD, Hofstetter WL, Ajani JA.

Oncology. 2017;93(4):243-248. doi: 10.1159/000475550. Epub 2017 Jul 6.

PMID:
28683449
18.

Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy.

Rogers JE, Bolonesi RM, Rashid A, Elsayes KM, Elbanan MG, Law L, Kaseb A, Shroff RT.

J Gastrointest Oncol. 2017 Apr;8(2):347-351. doi: 10.21037/jgo.2017.03.03.

19.

Patient considerations in metastatic colorectal cancer - role of panitumumab.

Rogers JE.

Onco Targets Ther. 2017 Apr 7;10:2033-2044. doi: 10.2147/OTT.S115430. eCollection 2017. Review.

20.

Families as Partners in Hospital Error and Adverse Event Surveillance.

Khan A, Coffey M, Litterer KP, Baird JD, Furtak SL, Garcia BM, Ashland MA, Calaman S, Kuzma NC, O'Toole JK, Patel A, Rosenbluth G, Destino LA, Everhart JL, Good BP, Hepps JH, Dalal AK, Lipsitz SR, Yoon CS, Zigmont KR, Srivastava R, Starmer AJ, Sectish TC, Spector ND, West DC, Landrigan CP; the Patient and Family Centered I-PASS Study Group, Allair BK, Alminde C, Alvarado-Little W, Atsatt M, Aylor ME, Bale JF Jr, Balmer D, Barton KT, Beck C, Bismilla Z, Blankenburg RL, Chandler D, Choudhary A, Christensen E, Coghlan-McDonald S, Cole FS, Corless E, Cray S, Da Silva R, Dahale D, Dreyer B, Growdon AS, Gubler L, Guiot A, Harris R, Haskell H, Kocolas I, Kruvand E, Lane MM, Langrish K, Ledford CJW, Lewis K, Lopreiato JO, Maloney CG, Mangan A, Markle P, Mendoza F, Micalizzi DA, Mittal V, Obermeyer M, O'Donnell KA, Ottolini M, Patel SJ, Pickler R, Rogers JE, Sanders LM, Sauder K, Shah SS, Sharma M, Simpkin A, Subramony A, Thompson ED Jr, Trueman L, Trujillo T, Turmelle MP, Warnick C, Welch C, White AJ, Wien MF, Winn AS, Wintch S, Wolf M, Yin HS, Yu CE.

JAMA Pediatr. 2017 Apr 1;171(4):372-381. doi: 10.1001/jamapediatrics.2016.4812. Erratum in: JAMA Pediatr. 2018 Mar 1;172(3):302.

21.

Parent and Provider Experience and Shared Understanding After a Family-Centered Nighttime Communication Intervention.

Khan A, Baird J, Rogers JE, Furtak SL, Williams KA, Allair B, Litterer KP, Sharma M, Smith A, Schuster MA, Landrigan CP.

Acad Pediatr. 2017 May - Jun;17(4):389-402. doi: 10.1016/j.acap.2017.01.012. Epub 2017 Jan 29.

22.

A Case Report-Stevens-Johnson Syndrome as an Adverse Effect of Capecitabine.

Jadhav P, Rogers JE, Shroff R.

J Gastrointest Cancer. 2018 Sep;49(3):349-350. doi: 10.1007/s12029-016-9916-3. No abstract available.

PMID:
28066869
23.

Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma.

Charalampakis N, Xiao L, Lin Q, Elimova E, Shimodaira Y, Harada K, Rogers JE, Mares J, Amlashi FG, Minsky BD, Das P, Hofstetter WL, Matamoros A Jr, Sagebiel TL, Blum-Murphy MA, Lee JH, Weston B, Bhutani MS, Mansfield PF, Estrella JS, Badgwell BD, Ajani JA.

Ann Surg Oncol. 2017 Aug;24(8):2291-2301. doi: 10.1245/s10434-016-5601-9. Epub 2016 Oct 21.

PMID:
27770339
24.

Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience.

Al-Shamsi HO, Fahmawi Y, Dahbour I, Tabash A, Rogers JE, Mares JE, Blum MA, Estrella J, Matamoros A Jr, Sagebiel T, Devine CE, Badgwell BD, Lin QD, Das P, Ajani JA.

J Gastrointest Oncol. 2016 Aug;7(4):499-505. doi: 10.21037/jgo.2016.06.16.

25.

Epidermal growth factor receptor inhibition in metastatic anal cancer.

Rogers JE, Ohinata A, Silva NN, Mehdizadeh A, Eng C.

Anticancer Drugs. 2016 Sep;27(8):804-8. doi: 10.1097/CAD.0000000000000383.

PMID:
27272412
26.

Communication and Shared Understanding Between Parents and Resident-Physicians at Night.

Khan A, Rogers JE, Forster CS, Furtak SL, Schuster MA, Landrigan CP.

Hosp Pediatr. 2016 Jun;6(6):319-29. doi: 10.1542/hpeds.2015-0224.

27.

Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors.

Shiozaki H, Slack RS, Chen HC, Elimova E, Planjery V, Charalampakis N, Wadhwa R, Shimodaira Y, Skinner H, Lee JH, Weston B, Bhutani MS, Blum-Murphy M, Rogers JE, Maru DM, Matamoros A Jr, Sagebiel T, Estrella JS, Das P, Hofstetter WL, Mares JE, Mizrak Kaya D, Harada K, Lin Q, Minsky BD, Badgwell BD, Ajani JA.

Oncology. 2016;91(1):55-60. doi: 10.1159/000445998. Epub 2016 Apr 28.

28.

The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation.

Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A Jr, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA.

Oncology. 2016;90(5):239-47. doi: 10.1159/000443506. Epub 2016 Apr 6.

29.

The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges.

Rogers JE, Dasari A, Eng C.

Oncologist. 2016 May;21(5):563-70. doi: 10.1634/theoncologist.2015-0362. Epub 2016 Mar 21. Review.

30.

Parent-Reported Errors and Adverse Events in Hospitalized Children.

Khan A, Furtak SL, Melvin P, Rogers JE, Schuster MA, Landrigan CP.

JAMA Pediatr. 2016 Apr;170(4):e154608. doi: 10.1001/jamapediatrics.2015.4608. Epub 2016 Apr 4.

31.

A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer.

Sudo K, Wang X, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Rice DC, Lee JH, Weston B, Bhutani MS, Hiremath A, Charalampakis N, Komaki R, Blum MA, Swisher SG, Maru DM, Skinner HD, Garris JL, Rogers JE, Hofstetter WL, Ajani JA.

J Natl Compr Canc Netw. 2016 Feb;14(2):173-9.

PMID:
26850487
32.

Commentary: Bringing Order to Chaos--How Psychiatrists Know the Standard of Care.

Rogers JE, Neumann CL, Myers WC.

J Am Acad Psychiatry Law. 2015 Dec;43(4):451-5.

PMID:
26668222
33.

Physician and Nurse Nighttime Communication and Parents' Hospital Experience.

Khan A, Rogers JE, Melvin P, Furtak SL, Faboyede GM, Schuster MA, Landrigan CP.

Pediatrics. 2015 Nov;136(5):e1249-58. doi: 10.1542/peds.2015-2391.

34.

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.

Bahleda R, Baker J, Massard C, Gadgeel SM, Rogers JE, Izzedine H, Deutsch E, Garris JL, Khan A, Boelle E, Assadourian S, Soria JC, Ajani JA.

Oncology. 2016;90(1):10-20. doi: 10.1159/000440958. Epub 2015 Oct 23.

PMID:
26492090
35.

Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal.

Rogers JE, Silva NN, Eng C.

J Gastrointest Oncol. 2015 Oct;6(5):E82-5. doi: 10.3978/j.issn.2078-6891.2015.035.

36.

Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively.

Charalampakis N, Xiao L, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Planjery V, Rogers JE, Matamoros A Jr, Sagebiel T, Das P, Lee JH, Bhutani MS, Weston B, Estrella JS, Badgwell BD, Ajani JA.

Oncology. 2015;89(6):305-10. doi: 10.1159/000436972. Epub 2015 Sep 23.

37.

18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.

Elimova E, Wang X, Etchebehere E, Shiozaki H, Shimodaira Y, Wadhwa R, Planjery V, Charalampakis N, Blum MA, Hofstetter W, Lee JH, Weston BR, Bhutani MS, Rogers JE, Maru D, Skinner HD, Macapinlac HA, Ajani JA.

Eur J Cancer. 2015 Nov;51(17):2545-52. doi: 10.1016/j.ejca.2015.07.044. Epub 2015 Aug 28.

38.

Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference?

Elimova E, Shiozaki H, Slack RS, Chen HC, Wadhwa R, Sudo K, Charalampakis N, Hiremath A, Estrella JS, Matamoros A, Sagebiel T, Das P, Rogers JE, Garris JL, Blum MA, Badgwell B, Ajani JA.

Oncology. 2015;89(4):215-20. doi: 10.1159/000434647. Epub 2015 Jul 8.

39.

Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications.

Neishaboori N, Wadhwa R, Nogueras-González GM, Elimova E, Shiozaki H, Sudo K, Charalampakis N, Hiremath A, Lee JH, Bhutani MS, Weston B, Blum MA, Rogers JE, Garris JL, Rice DC, Komaki R, Swisher SG, Skinner HD, Hofstetter WL, Ajani JA.

Oncology. 2015;89(2):65-9. doi: 10.1159/000371889. Epub 2015 Mar 5.

40.

Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma.

Shiozaki H, Slack R, Sudo K, Elimova E, Wadhwa R, Chen HC, Skinner HD, Komaki R, Lee JH, Weston B, Bhutani MS, Blum MA, Rogers JE, Maru DM, Hofstetter WL, Ajani JA.

Oncology. 2015;88(6):332-6. doi: 10.1159/000368611. Epub 2015 Feb 28.

41.

Ramucirumab for the treatment of gastroesophageal cancers.

Shimodaira Y, Elimova E, Wadhwa R, Shiozaki H, Charalampakis N, Planjery V, Rogers JE, Song S, Ajani JA.

Expert Opin Orphan Drugs. 2015;3(6):737-746. Epub 2015 May 25.

42.

Second-line systemic treatment for advanced cholangiocarcinoma.

Rogers JE, Law L, Nguyen VD, Qiao W, Javle MM, Kaseb A, Shroff RT.

J Gastrointest Oncol. 2014 Dec;5(6):408-13. doi: 10.3978/j.issn.2078-6891.2014.072.

43.

Tolerability of denosumab in metastatic solid tumor patients with renal insufficiency.

Watkins KR, Rogers JE, Atkinson B.

Support Care Cancer. 2015 Jun;23(6):1657-62. doi: 10.1007/s00520-014-2521-8. Epub 2014 Nov 25.

PMID:
25421444
44.

The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, Vauthey JN, Rogers JE, Ohinata A, Pathak P, Sethi S, Phillips JK, Crane CH, Wolff RA.

Oncotarget. 2014 Nov 30;5(22):11133-42.

45.

Cetuximab in refractory squamous cell carcinoma of the anal canal.

Rogers JE, Eng C.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:198-200. doi: 10.1007/s12029-014-9626-7. No abstract available.

PMID:
24908401
46.

Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal.

Rogers JE, Crane CH, Das P, Delclos M, Gould MS Jr, Ohinata A, Malatek D, Eng C.

Gastrointest Cancer Res. 2014 Mar;7(2):65-8. No abstract available.

47.

A case report--treatment of metastatic colorectal cancer in a patient on hemodialysis.

Bolonesi RM, Rogers JE, Shureiqi I.

J Gastrointest Cancer. 2014 Dec;45 Suppl 1:161-5. doi: 10.1007/s12029-014-9611-1. No abstract available.

PMID:
24756833
48.

Atypical metastatic presentations in colorectal cancer: a case series.

Rogers JE, Ohinata A, Dasari A, Eng C.

Clin Colorectal Cancer. 2014 Mar;13(1):e1-4. doi: 10.1016/j.clcc.2013.11.005. Epub 2013 Nov 12. No abstract available.

PMID:
24342822
49.

Commentary: the insanity defense and youths in juvenile court.

Rogers JE, Myers WC.

J Am Acad Psychiatry Law. 2013;41(4):496-500.

PMID:
24335320
50.

Isotretinoin maintenance therapy for glioblastoma: a retrospective review.

Chen SE, Choi SS, Rogers JE, Lei X, De Groot JF.

J Oncol Pharm Pract. 2014 Apr;20(2):112-9. doi: 10.1177/1078155213483348. Epub 2013 May 15.

PMID:
23676507

Supplemental Content

Loading ...
Support Center